Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade...